Ignite Creation Date:
2024-05-05 @ 4:39 PM
Last Modification Date:
2024-10-26 @ 9:22 AM
Study NCT ID:
NCT00281541
Status:
COMPLETED
Last Update Posted:
2012-06-07
First Post:
2006-01-23
Brief Title:
A Study for the Treatment of Unresectable Stage III or Metastatic Stage IV Melanoma
Sponsor:
Astellas Pharma Inc
Organization:
Astellas Pharma Inc
Study Overview
Official Title:
A Phase II Multicenter Open-Label Study of YM155 in Subjects With Unresectable Stage III or Metastatic Stage IV Melanoma
Status:
COMPLETED
Status Verified Date:
2012-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A study with YM155 for the treatment of unresectable stage III or metastatic stage IV melanoma
Detailed Description:
A phase II multicenter open-label study in subjects with unresectable Stage III or metastatic Stage IV Melanoma to evaluate the efficacy and safety of YM155
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None